Navigating the Evolving Acute Lymphoblastic Leukemia Treatment Paradigm - Episode 5
Other Possible Research Avenues for Blinatumomab in ALL
Ongoing research explores the logistics and efficacy of blinatumomab, aiming to enhance patient access and treatment outcomes in leukemia therapy.
Jonathan Webster, MD, and Nikesh Shah, MD, explore future research directions for blinatumomab in ALL, including combination strategies, sequencing questions, and potential synergy with next-generation targeted agents. They also consider how novel immunotherapies and evolving MRD-driven treatment paradigms may shape upcoming clinical investigations.
Related Content:
